Randomised comparison of partial liquid ventilation, nebulised perfluorocarbon, porcine surfactant, artificial surfactant, and combined treatments on oxygenation, lung mechanics, and survival in rabbits after saline lung lavage.
OBJECTIVE
To compare gas exchange, lung mechanics, and survival to 12 h in surfactant-depleted lung-injured rabbits, treated with partial liquid ventilation (PLV) with perfluorocarbon, nebulised perfluorocarbon, and porcine or artificial surfactant.


METHODS
Prospective randomised controlled study.


METHODS
Animal laboratory, University of Edinburgh, UK.


METHODS
Eighty-two adult female New Zealand white rabbits with surfactant deficiency and acute lung injury induced by repeated saline lavage.


METHODS
Animals were randomised to one of seven treatments: (a) control (n = 20); (b) PLV with perfluorocarbon PF 5080 (n = 12); (c) nebulised PF 5080 (n = 10); (d) artificial surfactant (n = 10); (e) porcine surfactant (n = 10); (f) artificial surfactant+PLV (n = 10); (g) porcine surfactant+PLV (n = 10).


RESULTS
Arterial blood gases and dynamic compliance (Cdyn) were measured hourly until 12 h. Oxygenation was improved by PLV, porcine surfactant, porcine surfactant+PLV and artificial surfactant+PLV. Cdyn improved after treatment with PLV, porcine surfactant and PLV+porcine surfactant. Survival was greater with PLV and artificial surfactant+PLV. Neither nebulised PF 5080 nor artificial surfactant had a detectable effect.


CONCLUSIONS
PLV, porcine surfactant and combinations of surfactant with PLV improved oxygenation, Cdyn and survival, but none was clearly superior to the others.
Kelly
K P
KP
The University Department of Anaesthetics, The Royal Infirmary of Edinburgh, UK. Keith.Kelly@ed.ac.uk
Stenson
B J
BJ
Drummond
G B
GB
D000280:Administration, Inhalation; D000818:Animals; D001688:Biological Products; D001784:Blood Gas Analysis; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D005466:Fluorocarbons / Q000494:pharmacology / Q000627:therapeutic use*; D021061:Liquid Ventilation / Q000379:methods*; D008170:Lung Compliance / Q000187:drug effects*; D010743:Phospholipids / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D011659:Pulmonary Gas Exchange / Q000187:drug effects*; D011663:Pulmonary Surfactants / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D011897:Random Allocation; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000378:metabolism / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D012965:Sodium Chloride; D016019:Survival Analysis; D013552:Swine; D007507:Therapeutic Irrigation; D016896:Treatment Outcome
D001688:Biological Products; D005466:Fluorocarbons; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068829:artificial lung expanding compound; D012965:Sodium Chloride; C068291:poractant alfa